Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin heavy diversity 1-1 (IGHD1-1) is one of multiple diversity (D) gene segments in the human immunoglobulin heavy chain locus, located on chromosome 14q32. These D segments are critical for the generation of antibody diversity, as they are recombined with variable (V) and joining (J) segments during B-cell development. This recombination process, known as V(D)J recombination, allows B lymphocytes to produce a vast array of different immunoglobulins with distinct antigen specificities. The IGHD1-1 segment itself encodes part of the antigen-binding site of the immunoglobulin heavy chain[1][2][3]. It is a DNA segment, not an expressed protein or receptor. Variation in the IGH locus, including IGHD1-1, contributes to differences in immune function and disease susceptibility but is not itself a functional protein or receptor amenable to drug targeting[1][3]. IGHD1-1 is often confused with immunoglobulin heavy chain constant regions or actual immunoglobulin receptors, which are functional proteins targeted by therapeutics (e.g., anti-IgG therapies). IGHD1-1 is a genetic segment; its main function is to contribute genetic diversity in antibodies, not to serve as a drug target or biomarker itself. A query that seeks a receptor, enzyme, or other classical target should not map IGHD1-1 as a valid or actionable therapeutic target[1][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin heavy diversity 1-1 (IGHD1-1).